Dacomitinib is a cancer medicine that interferes with the growth and spread of cancer cells in the body. It is used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic). Dacomitinib is usually given after other cancer medicines have been tried without success. It is also used as a first-line treatment for certain types of advanced NSCLC that has a certain type of epidermal growth factor receptor (EGFR) gene mutation. Dacomitinib is also used in combination with other cancer medicines for treating NSCLC.
Dacomitinib is a medication used to treat a specific type of lung cancer. Here's a breakdown of its key features:
Cancer Type:
- Dacomitinib is primarily used for treating non-small cell lung cancer (NSCLC) with specific mutations in the epidermal growth factor receptor (EGFR) gene.
- EGFR mutations are alterations in a gene that can fuel the growth and spread of certain cancers, including lung cancer.
How it Works:
- Dacomitinib belongs to a class of drugs called tyrosine kinase inhibitors (TKIs).
- TKIs target specific proteins involved in cell growth and division.
- In NSCLC with EGFR mutations, Dacomitinib works by blocking the abnormal EGFR protein, thereby interrupting cancer cell growth and spread.
Administration:
- Dacomitinib comes in tablet form taken orally, typically once a day.
Important Considerations:
- Dacomitinib is only used for NSCLC with specific EGFR mutations identified through a genetic test on tumor tissue.
- A doctor will determine if Dacomitinib is the right treatment option based on your individual test results.
- Dacomitinib can cause side effects, such as diarrhea, skin rash, dry skin, and inflammation of the mouth and throat.
- It's crucial to consult a doctor before using Dacomitinib to discuss potential side effects, interactions with other medications, and proper monitoring during treatment.
Overall:
Dacomitinib is a targeted therapy medication for a specific type of lung cancer. It works by blocking a mutated protein that drives cancer cell growth. If you have NSCLC, your doctor will perform genetic testing to see if Dacomitinib is a potential treatment option for you.